Yuyu Pharma, Inc. Stock price

Equities

A000220

KR7000220004

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5,140 KRW -0.96% Intraday chart for Yuyu Pharma, Inc. +0.59% -2.65%
Sales 2022 139B 103M Sales 2023 137B 102M Capitalization 85.44B 63.57M
Net income 2022 -5.99B -4.46M Net income 2023 -7.18B -5.34M EV / Sales 2022 0.8 x
Net Debt 2022 8.5B 6.32M Net Debt 2023 7.05B 5.25M EV / Sales 2023 0.67 x
P/E ratio 2022
-16.4 x
P/E ratio 2023
-11.9 x
Employees 318
Yield 2022
1.69%
Yield 2023
-
Free-Float 51.37%
More Fundamentals * Assessed data
Dynamic Chart
Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Yuyu Pharma, Inc. announced that it has received KRW 24.5 billion in funding from a group of investors CI
Yuyu Pharma, Inc. announced that it expects to receive KRW 24.5 billion in funding from a group of investors CI
Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Yuyu Pharma Unveils the Results of Its Mechanism of Action and Head-To- Head Studies for Its Dry Eye Treatment Peptide CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Tranche Update on Yuyu Pharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. CI
Tranche Update on Yuyu Pharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. CI
Yuyu Pharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed with 304,878 shares, representing 1.83% for KRW 1,785.24 million. CI
Yuyu Pharma, Inc. announces an Equity Buyback for 304,878 shares. CI
Yuyu Pharma, Inc. authorizes a Buyback Plan. CI
Yuyu Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Disease CI
Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day-0.96%
1 week+0.59%
Current month+7.53%
1 month+6.09%
3 months-2.65%
6 months+13.34%
Current year-2.65%
More quotes
1 week
5 140.00
Extreme 5140
5 810.00
1 month
4 660.00
Extreme 4660
5 810.00
Current year
4 660.00
Extreme 4660
6 730.00
1 year
4 160.00
Extreme 4160
7 440.00
3 years
4 160.00
Extreme 4160
18 950.00
5 years
3 460.00
Extreme 3460
18 950.00
10 years
3 415.00
Extreme 3415
18 950.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 20-04-05
Corporate Officer/Principal 65 -
Members of the board TitleAgeSince
Chief Executive Officer 50 20-04-05
Director/Board Member 83 -
Director/Board Member 43 17-05-30
More insiders
Date Price Change Volume
24-03-28 5,140 -0.96% 96,297
24-03-27 5,190 -0.57% 174,350
24-03-26 5,220 -1.32% 1,533,271
24-03-25 5,290 +1.34% 224,723
24-03-22 5,220 +2.15% 479,300

End-of-day quote Korea S.E., March 27, 2024

More quotes
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Yuyu Pharma, Inc. - Korea S.E.